IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
October 31 2024 - 8:30AM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
DNA-mediated immunotherapy and next-generation vaccines, announces
that the Company will host a conference call at 11:00 a.m. ET on
Thursday, November 7, 2024 to discuss financial results for the
third quarter ended September 30, 2024 and provide an update on its
clinical development programs with IMNN-001, a DNA-based
interleukin-12 (IL-12) immunotherapy for the treatment of
first-line, locally advanced-stage ovarian cancer, and on its
PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA
delivery technology for the expression of pathogen antigens for the
development of next-generation vaccines.
To participate in the call, interested parties
may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711
(International/Toll) and ask for the IMUNON Third Quarter 2024
Earnings Call. A live webcast of the call will also be available
here.
The call will be archived for replay until
November 21, 2024, and can be accessed at 877-344-7529 (U.S. Toll
Free), 855-669-9658 (Canada Toll Free) or 412-317-0088
(International Toll) using replay access code 6852891. An audio
replay of the call will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company
focused on advancing a portfolio of innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases,
constituting a differentiating approach from conventional
therapies. IMUNON is developing its non-viral DNA technology across
its modalities. The first modality, TheraPlas®, is developed for
the coding of cytokines and other therapeutic proteins in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
delivery of DNA-coded viral antigens that can elicit a strong
immunological response.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer that has completed Phase 2 development.
IMNN-001 works by instructing the body to produce safe and durable
levels of powerful cancer-fighting molecules, such as
interleukin-12 and interferon gamma, at the tumor site.
Additionally, the Company has entered a first-in-human study of its
COVID-19 booster vaccine (IMNN-101). IMUNON will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information, please
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical fact, including, but not limited to,
statements regarding the timing for commencement of a Phase 3 trial
of IMNN-001, the timing and outcome of the Company’s End-of-Phase 2
meeting with the FDA, the timing and enrollment of the Company’s
clinical trials, the potential of any therapies developed by the
Company to fulfill unmet medical needs, the market potential for
the Company’s products, if approved, the potential efficacy and
safety profile of our product candidates, and the Company’s plans
and expectations with respect to its development programs more
generally, are forward-looking statements. We generally identify
forward-looking statements by using words such as “may,” “will,”
“expect,” “plan,” “anticipate,” “estimate,” “intend” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances). Readers are cautioned
that such forward-looking statements involve risks and
uncertainties including, without limitation, uncertainties relating
to unforeseen changes in the course of research and development
activities and in clinical trials, including the fact that interim
results are not necessarily indicative of final results; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to
evaluate its future development plans; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s filings with
the Securities and Exchange
Commission. IMUNON assumes no obligation, except to the
extent required by law, to update or supplement forward-looking
statements that become untrue because of subsequent events, new
information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
David Gaiero |
Kim Sutton Golodetz |
978-376-6352 |
212-838-3777 |
dgaiero@imunon.com |
kgolodetz@lhai.com |
# # #
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From Dec 2023 to Dec 2024